Furthermore, based on the mutation profiles in three of the 11 genes (ROS1, SPEN, and PTPRT), we defined the TMB prognostic score that could predict cancer survival prognosis in the immunotherapy setting but not in the non-immunotherapy setting. This evidence concerns the gene PTPRT and cancer.